The pressure is on for those earnings to support the market's current valuations, after weeks of choppy trading.» Read More
Eli Lilly and Takeda Pharmaceutical were ordered to pay billions in damages over claims that they concealed cancer risks of its Actos diabetes drug.
*Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close. *Earnings season gets under way this week, with results due from companies including Alcoa Inc after the close, retailer Bed, Bath& Beyond on Wednesday, while financials JPMorgan Chase& Co and Wells Fargo& Co close out the week with results on Friday.
*Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. SAN FRANCISCO/ TOKYO, April 8- Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.
TOKYO— A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The U. S District Court in western Louisiana ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly.
*Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. TOKYO, April 8- A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in damages over claims that it concealed cancer risks associated with its Actos diabetes drug, the plaintiffs' lawyer said on Tuesday.
April 8- A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in punitive damages and Eli Lilly and Co to pay $3 billion in a case claiming that cancer risks to the diabetes drug Actos were concealed, the plaintiffs' lawyer said. The jury in Lafayette, Louisana also order the payment of $1.475 million in compensatory damages in the suit.
Baxter International Inc. fell$. 44 or. 6 percent, to $72.49. Bristol-Myers Squibb Co. rose$. 39 or. 8 percent, to $50.28. Hospira fell$. 37 or. 9 percent, to $43.01.
Baxter International Inc. rose$. 06 or. 1 percent, to $72.99. Bristol-Myers Squibb Co. rose$. 39 or. 8 percent, to $50.28. Hospira fell$. 55 or 1.3 percent, to $42.83.
April 6- Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. The U.S. Food and Drug Administration has granted "breakthrough" status for palbociclib.
Baxter International Inc. fell$. 46 or. 6 percent, to $72.93. Bristol-Myers Squibb Co. fell$. 98 or 1.9 percent, to $49.89. Hospira fell $1.17 or 2.6 percent, to $43.38.
Baxter International Inc. rose$. 26 or. 3 percent, to $73.64. Bristol-Myers Squibb Co. fell$. 08 or. 2 percent, to $50.79. Hospira fell $1.15 or 2.6 percent, to $43.40.
Baxter International Inc. rose$. 24 or. 3 percent, to $73.63. Bristol-Myers Squibb Co. rose$. 60 or 1.2 percent, to $51.47. Hospira fell$. 50 or 1.1 percent, to $44.05.
U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Some of the names on the move ahead of the open.
March 31- Eli Lilly was successful in a crucial legal battle on Monday when a U.S. The court said the defendants, Teva Pharmaceutical Industries Ltd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of the' 209 Patent are invalid.
March 31- Prana Biotechnology Ltd lost nearly three-quarters of its value after the company said its experimental drug to treat Alzheimer's disease failed a mid-stage study, raising doubts about the drug's future.
March 24- Data storage provider Box Inc aims to raise about $250 million in an initial public offering, becoming the latest contender from a wave of "cloud-based" companies to test the frothy market for technology listings.
COPENHAGEN, March 20- Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday.
March 12- The number of U.S. cattle deaths that may be linked to the Merck& Co Inc feed additive Zilmax are much higher than the figures reported by the drug company to the federal government, according to a research study published on Wednesday.